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Cadmium is a common environmental cont-
aminant and is associated with nephrotoxic
effects, particularly at high exposure levels
(1). Various tests with differing degrees of
sensitivity and clinical signiﬁcance have been
used among cadmium-exposed populations
to assess nephrotoxicity. Among these, ele-
vated urinary albumin in the absence of an
increase in low-molecular-weight protein
excretion is an early indicator of glomerular
damage and is observed at urine cadmium
concentrations from 3.6 to 4.2 µg urinary
cadmium/g creatinine (2). Increased albumin
excretion and proteinuria is associated with
excess cardiovascular disease, mortality, and
renal disease (3), but these clinical implica-
tions have not been specifically associated
with cadmium toxicity. Elevations in the
excretion of low-molecular-weight proteins,
such as β2-microglobulin, α1-microglobulin,
or retinol-binding protein, have been used as
indicators of damage to the tubular protein
absorption capability. Low-molecular-weight
proteinuria among exposed workers with
> 10 µg urinary cadmium/g creatinine was
irreversible and exacerbated the age-related
decline in the glomerular filtration rate
(4–6). Elevations in enzymes primarily of
renal tubular origin, such as N-acetyl-β-D-
glucosaminidase (NAG) and alanine
aminopeptidase (AAP), have been observed
at occupational cadmium exposures of
3.7–6.3 µg urinary cadmium/g creatinine
(2,4,7). Increases in these enzymes have been
associated with chemical-induced renal
tubular damage (8,9)
Most studies of cadmium-induced renal
effects using these and other biomarkers have
been conducted among individuals with
occupational or high environmental expo-
sures (4,7,10–16). Results of a national
health survey indicate that the geometric
mean value (and 95th percentile) for urinary
cadmium among the U.S. general population
age 6 years or older is approximately 0.27
(1.48) µg/g creatinine (17), but little infor-
mation is available on renal effects that may
occur in people with urinary cadmium levels
< 2 µg/g. Recent findings indicate that
changes in sensitive renal biomarkers may
occur at lower urinary cadmium levels than
previously estimated among populations
exposed to environmental cadmium (18–21).
The data for this study were collected in
1991 by the Agency for Toxic Substances
and Disease Registry in a small community
in the northeastern United States that had
been the site of zinc smelting operations
from 1898 through 1980 and in a nearby
community that was demographically simi-
lar to the target area (22,23). Exposure
among adults could reflect past airborne
routes and possibly occupational exposure, as
people from both towns worked in industrial
jobs. Exposure among children reflects pri-
marily contact with contaminated soil. The
objective of this study was to determine the
extent to which exposure to cadmium in these
individuals was associated with biomarkers of
early kidney damage. The panel of biomark-
ers consisted of two high-molecular-weight
proteins, NAG and AAP, to indicate direct
release of kidney tubular tissue into urine;
the intermediate-molecular-weight protein
albumin to indicate glomerular damage
when excretion of low-molecular-weight
protein was normal; and the low-molecular-
weight protein β2-microglobulin to indicate
impaired tubular reabsorption.
Methods
Study participants included residents of
Palmerton and Aquashicola, Pennsylvania,
a community with past zinc smelting activ-
ity, and residents of East Jim Thorpe,
Pennsylvania, a comparison community
located approximately 10 miles from the
defunct smelting facility. We selected the
comparison area on the basis of similar
demographics and age of housing, and
because it was not affected by zinc smelting,
coal mining, or other heavy industrial opera-
tions. Because previous analyses found that
urinary cadmium levels among these study
participants did not differ by area of resi-
dence (22,23), we combined individuals
from both target and comparison communi-
ties to evaluate the effect of low-level cad-
mium exposure on kidney biomarkers. A
complete door-to-door census was taken to
determine the total population and to gen-
erate a list of eligible residents. Random
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Articles
We conducted a study among residents of a small community contaminated with heavy metals
from a defunct zinc smelter and residents from a comparison community to determine whether
biologic measures of cadmium exposure were associated with biomarkers of early kidney damage.
Creatinine-adjusted urinary cadmium levels did not differ between the smelter and comparison
communities; thus we combined individuals from both communities (n = 361) for further analy-
ses. The overall mean urinary cadmium level was low, 0.26 µg/g creatinine, similar to reference
values observed in the U.S. general population. For children ages 6–17 years, urinary concentra-
tion of N-acetyl-β-D-glucosaminidase (NAG), alanine aminopeptidase (AAP), and albumin were
positively associated with urinary cadmium, but these associations did not remain statistically sig-
niﬁcant after adjusting for urinary creatinine and other potential confounders. For adults ages 18
or older, urinary concentration of NAG, AAP, and albumin were positively associated with uri-
nary cadmium. The associations with NAG and AAP but not with albumin remained statistically
significant after adjusting for creatinine and other potential confounders. We found a positive
dose–effect relationship between levels of creatinine-adjusted urinary cadmium and NAG and
AAP activity, and statistically significant differences in mean activity for these two enzymes
between the highest (≥ 1.0 µg cadmium/g creatinine) and the lowest (< 0.25 µg cadmium/g crea-
tinine) exposure groups. The ﬁndings of this study indicate that biologic measures of cadmium
exposure at levels below 2.0 µg/g creatinine may produce measurable changes in kidney biomark-
ers. Key words: alanine aminopeptidase, albumin, β2-microglobulin, cadmium, kidney, N-acetyl-
β-D-glucosaminidase. Environ Health Perspect 110:151–155 (2002). [Online 16 January 2002]
http://ehpnet1.niehs.nih.gov/docs/2002/110p151-155noonan/abstract.htmlsamples of residents, 6 months through 75
years of age, who had resided in their homes
during the 6 months previous to the study
were selected. The mean time of residency
among adults in their respective communi-
ties was 32 years. Trained interviewers
administered a standardized questionnaire,
which included information on occupational
exposures, health status, and health behav-
iors (e.g., lifetime consumption of alcohol
and tobacco). Parents or guardians answered
questions for children under 12 years of age.
Informed consent was obtained from the
participants or from the parent or guardian
of minors.
Specimen collection and analyses. We col-
lected spot urine specimens from participants
to measure cadmium, AAP, NAG, albumin,
β2-microglobulin, and creatinine. Cadmium-
free collection materials were provided by the
National Center for Environmental Health
(NCEH), Division of Environmental Health
Laboratory Services, Centers for Disease
Control and Prevention, Atlanta, Georgia.
Urine samples were frozen and sent by
overnight delivery to NCEH, Division of
Environmental Health Laboratory Services,
for analysis. 
We determined urine cadmium levels
using established procedures (7,24), and
quality-control procedures included per-
forming 10% replicates and 5–15% controls
and using field blanks for urine cadmium
tests. As described previously, AAP was
measured by an automated Jung and Scholz
method (25), and NAG was measured by
the Leaback and Walker method (26) and
automated for the centrifugal analyzer
Cobas Fara II (Roche Diagnostic Systems,
Basel, Switzerland) (27). We measured albu-
min by enzyme immunosorbent assay, and
assayed β2-microglobulin using Pharmacia
Diagnostics Phadebas β2-Microglobulin Test
Kits (Uppsala, Sweden) (7). Quality-control
design for AAP, NAG, albumin, and
β2-microglobulin involved three bench pools,
assayed in duplicate in each run. We mea-
sured urinary creatinine with an automated
clinical Kodak 250 Analyzer (Ortho Clinical
Diagnostics, Rochester, NY) using a single-
slide, two-point enzymatic method according
to the manufacturer’s directions. Quality-
control design for creatinine involved one
low-, one medium- and one high-control
analyzed in quadruplicate per run. 
Data adjustment and exclusion criteria.
We used urine creatinine to control for dif-
ferences in urine dilution. Urine creatinine
concentrations are proportional to muscle
mass and vary by age and sex (28). We were
able to adjust for age and sex in the multi-
variate analyses but not for muscle mass
because height and weight data were not col-
lected. Urine specimens with creatinine levels
< 30 mg/dL were not included in the analy-
ses, to eliminate the potential for imprecise
and unreliable results from highly dilute
urine samples. One creatinine-adjusted albu-
min value, 1,585 mg/g, was excluded from
the analyses because it was well above the
95th percentile for the study, 45 mg/g. This
single value would have inflated the mean
urinary albumin concentration by 36% in
the group of participants with the highest
urinary cadmium values (≥ 1.0 µg/g creati-
nine). When this albumin value was
included in the analyses, no change was
observed in the nonparametric correlation
analysis. Urine specimens with cadmium
measures below the detection limit (0.1
µg/L) were assigned a value of one-half the
detection limit. Our findings were similar
when these individuals were excluded from
the analyses. The results presented below
excluded the lowest age group, 6–71 months
of age, because 45% of this group had creati-
nine values < 30 mg/dL and 69% had uri-
nary cadmium levels below the detection
limit. We also excluded 164 urine samples
with a pH less than 6.0 from the analysis of
β2-microglobulin because this protein is
unstable in acidic media (29). 
Six participants with self-reported kidney
disease were removed from the analyses.
Adults reporting diabetes (n = 6) and thyroid
disease (n = 6) had higher urinary cadmium
levels, and these conditions were associated
with at least one of the kidney biomarkers.
Variables to indicate the self-reporting of
these two diseases were included in the mul-
tivariate analyses for adults. Other self-
reported conditions such as hepatitis, other
urinary tract disease, arthritis, leukemia, or
other cancer were not associated with the
biomarkers, and participants reporting these
conditions remained in the analyses. The
magnitude of effect between urinary cad-
mium and the kidney biomarkers did not
change when individuals with these reported
conditions were removed from the analyses.
Among children, those reporting diabetes
(n = 1) or thyroid disease (n = 1) were
removed from the analyses. 
Data analysis. Statistical analyses were
done with version 6.12 of the Statistical
Analysis Software (SAS; SAS Institute, Inc.,
Cary, NC, USA). All biologic test data were
log-transformed for statistical analysis to
approximate normality. We assessed differ-
ences in creatinine-adjusted urinary cad-
mium and creatinine-adjusted renal
biomarker values by area of residence, age,
sex, medical conditions, and behavioral fac-
tors using analysis of variance. 
Recent studies indicate that children are
more likely to have high urinary albumin
concentrations (30,31), an association that
may be attributed partially to stage of
puberty (30). Given this and the possibility
that other biomarkers may be affected in a
similar manner, we performed separate corre-
lation analyses for adults aged 18 years or
older, and children 6–17 years. We calcu-
lated crude Spearman correlation coefﬁcients,
uncorrected for creatinine, for each kidney
biomarker with urinary cadmium. We calcu-
lated partial Spearman correlation coefﬁcients
for adults after adjusting for creatinine, age,
sex, smoking, and self-reported diabetes or
thyroid disease. We also calculated partial
Spearman correlation coefﬁcients for children
after adjusting for creatinine, age, and sex.
To characterize dose–effect relationships
between urinary cadmium and the kidney
proteins and enzymes, we grouped adult par-
ticipants into five categories of creatinine-
adjusted urinary cadmium. We used
Dunnett’s two-tailed t-test to determine
whether the mean enzyme activity or protein
concentration for each of the four higher
categories of creatinine-adjusted urinary cad-
mium was significantly different from the
lowest category (i.e., < 0.25 µg cadmium/g
creatinine). We then calculated least-squares
means by exposure group, adjusted for age,
sex, smoking, and self-reported diabetes or
thyroid disease, for each of the creatinine-
adjusted kidney biomarkers. The differences
between the adjusted mean levels of each
kidney biomarker in the high- and low-
exposure groups were compared statistically,
using the least-signiﬁcant-difference method
in SAS. 
Results
We collected urine samples from 361 per-
sons, ages 6 through 74 years, reflecting a
50% participation rate for the comparison
area and a 64% participation rate for the
smelter (target) area. Of these, 46 had creati-
nine values < 30 mg/dL, and some individu-
als did not have valid data for one or more of
the renal biomarkers. The geometric mean
(and 95th percentile) creatinine-adjusted
urinary cadmium was 0.13 µg/g creatinine
(1.01). Only three subjects had values > 2.0
µg/g creatinine, with the maximum value at
2.15 µg/g creatinine. Geometric mean values
of creatinine-adjusted urinary cadmium and
renal biomarkers for selected variables are
presented in Table 1. Area of residence was
not associated with concentrations of urinary
cadmium or renal biomarkers. We observed
differences between males and females for
some of the renal biomarkers but not for uri-
nary cadmium. Among participants who
smoke cigarettes, pack-years (i.e., the num-
ber of cigarette packs per day multiplied by
the number of years smoking) was positively
associated with urinary cadmium, and there
was a linear relationship between pack-years
and some of the kidney biomarkers. 
Articles • Noonan et al.
152 VOLUME 110 | NUMBER 2 | February 2002 • Environmental Health PerspectivesResults from the correlation analyses are
presented in Table 2. For children ages 6–17
years, urinary cadmium was associated with
NAG, AAP, and albumin. None of these
biomarkers remained signiﬁcantly associated
with cadmium after adjusting for creatinine,
age, and sex. β2-Microglobulin was not asso-
ciated with urinary cadmium for this age
group. For adults age 18 years or older, uri-
nary cadmium was also positively associated
with NAG, AAP, and albumin. After adjust-
ing for creatinine, age, sex, smoking, and
self-reported diabetes or thyroid disease, the
partial correlations for urinary cadmium
with NAG and AAP remained statistically
signiﬁcant (p < 0.05 for each enzyme). The
partial correlation coefﬁcient for urinary cad-
mium with albumin was reduced in compar-
ison with the crude correlation and was no
longer statistically signiﬁcant. The observed
correlations were of a similar direction and
magnitude when target and comparison
areas were analyzed separately (data not
shown).
When the adults were grouped by five
creatinine-adjusted urinary cadmium levels,
the mean enzyme activity levels for both
NAG and AAP demonstrated a positive lin-
ear relationship. Individuals in the highest
exposure group (≥ 1.0 µg cadmium/g creati-
nine) had statistically signiﬁcant increases of
53% and 43% for NAG and AAP, respec-
tively, when compared with the lowest expo-
sure group (< 0.25 µg cadmium/g
creatinine) (data not shown). After adjusting
for age, sex, smoking, and self-reported dia-
betes or thyroid disease, the differences in
the mean levels of NAG and AAP between
the highest and lowest categories of urinary
cadmium remained statistically significant.
These two enzymes demonstrated a positive
dose–effect relationship among adult partici-
pants across the ﬁve categories of creatinine-
adjusted urinary cadmium (Figure 1A,B).
For mean concentrations of both albumin
and β2-microglobulin grouped by the five
categories of creatinine-adjusted urinary cad-
mium, we found no consistent linear rela-
tionship (data not shown).
Discussion
The geometric mean urinary cadmium level
among adults in this study (0.23 µg/g creati-
nine) is similar to the levels found in the
U.S. general population (0.27 µg/g creati-
nine) (17). The ﬁnding of a positive associa-
tion between urinary cadmium and renal
biomarkers is consistent with the results of
previous studies that found a positive associ-
ation between cadmium and kidney enzymes
and proteins at higher exposure levels
(4,7,10–16). The enzymes NAG and AAP
are not normally filtered through the
glomerulus, so their presence in urine may
indicate subclinical proximal tubular injury
(29). AAP is localized to the brush border of
the proximal tubule, and release of this
enzyme may indicate membrane damage to
tubular cells. The lysosomal enzyme NAG
also is present in high concentrations in
proximal tubule cells (29). NAG in urine is
associated with increased necrotic or apop-
totic cell turnover, but its presence can result
from effects other than nephrotoxicity (32).
An association between AAP and urinary
cadmium was previously observed in studies
of individuals with high occupational expo-
sures (7,11), and NAG has been used as a
marker of cadmium nephrotoxicity in several
occupational and environmental studies
(7,10–12,33,34). 
The evaluation of different exposure levels
in our study sample suggested a dose–effect
relationship at levels < 2.0 µg urinary cad-
mium/g creatinine. Previous studies of highly
exposed populations have demonstrated
threshold of effects for renal biomarkers at
2.4–11.5 µg urinary cadmium/g creatinine
(2,4). However, recent studies have found
that effects may be seen at lower levels in the
general population. A cross-sectional study
in Sweden found that people with 1.0 µg
urinary cadmium/g creatinine had a 3-fold
increase in risk of having tubular protein-
uria, as measured by α1-microglobulin (21).
Total NAG was also associated with creati-
nine-adjusted urinary cadmium (p < 0.05 for
linear regression) among an environmentally
exposed population in Sweden with rela-
tively low urinary cadmium concentrations
(median = 1.0 µg cadmium/g creatinine,
range = 0.1–3.2 µg cadmium/g creatinine)
(20). A study conducted in areas of Japan
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Table 2. Spearman correlation coefficients (95% confidence interval) between urinary cadmium levels
and biomarkers of early kidney damage.
NAG AAP Albumin β2-Microglobulin
Urinary cadmium (U/L) (U/L) (mg/L) (mg/L)
Age 6–17 years (n) 159 159 159 105
Crude correlation 0.25 0.24 0.17 0.09
(0.10–0.40) (0.10–0.39) (0.02–0.32) (–0.10–0.29)
Partial correlationa 0.09 0.15 0.03 –0.01
(–0.07–0.24) (0.00–0.30) (–0.12–0.19) (–0.20–0.19)
Age ≥ 18 years (n) 150 150 150 63
Crude correlation 0.30 0.37 0.26 0.18
(0.15–0.44) (0.23–0.51) (0.12–0.41) (–0.06–0.43)
Partial correlationb 0.20 0.21 0.09 –0.02
(0.05–0.36) (0.05–0.36) (–0.07–0.25) (–0.27–0.24)
aAdjusted for creatinine, age, and sex. bAdjusted for creatinine, age, sex, smoking, and self-reported diabetes or thyroid
disease. 
Table 1. Geometric mean values (95% conﬁdence intervals) of urinary markers for selected characteristics.
Cadmium NAG AAP Albumin β2-Microglobulin
Characteristics No.a (µg/g creatinine) (Ug/g creatinine) (Ug/g creatinine) (mg/g creatinine) (mg/g creatinine)
Area
Smelter 168 0.14 (0.12–0.17) 0.73 (0.65–0.81) 4.38 (3.98–4.82) 7.34 (6.58–8.19) 0.13 (0.11–0.14)
Comparison 144 0.12 (0.10–0.14) 0.73 (0.65–0.82) 4.62 (4.20–5.09) 8.45 (6.58–9.73) 0.12 (0.10–0.13)
Age/sex
6–17 years
Female 71 0.08 (0.07–0.10) 0.82 (0.74–0.92)* 4.53 (3.99–5.13) 10.38 (8.76–12.30)* 0.12 (0.10–0.14)
Male 88 0.07 (0.06–0.08) 0.57 (0.50–0.63) 4.50 (3.96–5.12) 7.00 (6.08–8.06) 0.12 (0.10–0.14)
≥ 18 years
Female 80 0.23 (0.18–0.30) 0.83 (0.69–1.00) 3.82 (3.25–4.49)* 7.96 (6.68–9.48) 0.14 (0.11–0.19)
Male 71 0.24 (0.18–0.32) 0.75 (0.62–0.90) 5.30 (4.68–6.00) 6.67 (5.36–8.30) 0.11 (0.09–0.13)
Smoking (pack-years)b
06 9 0.18 (0.14–0.22)* 0.85 (0.69–1.03) 4.39 (3.68–5.23)** 7.64 (6.20–9.42) 0.11 (0.10–0.13)
< 10 27 0.16 (0.10–0.25) 0.65 (0.46–0.92) 3.82 (3.18–4.60) 5.80 (4.49–7.49) 0.12 (0.08–0.20)
< 30 29 0.35 (0.23–0.53) 0.74 (0.53–1.03) 4.02 (3.14–5.17) 6.49 (4.76–8.86) 0.17 (0.08–0.36)
≥ 30 23 0.56 (0.40–0.79) 0.89 (0.66–1.20) 6.42 (5.07–8.13) 10.45 (6.69–16.33) 0.13 (0.06–0.29)
aNumber of subjects for each biomarker vary because of missing values. bData on smoking for adults only. *p < 0.01, analysis of variance. **p < 0.05, analysis of variance. with no industrial cadmium exposures
observed geometric mean urinary values of
1.3 µg cadmium/g creatinine and found a
significantly positive association for NAG
and β2-microglobulin (18). Another investi-
gation combining cadmium-exposed smelter
workers with members of a control group
found signiﬁcant elevations of NAG among
those excreting 0.5–2.0 µg cadmium/g crea-
tinine, compared with those excreting < 0.5
µg cadmium/g creatinine (12). 
In the present study, we observed statisti-
cally signiﬁcant positive correlations between
urinary albumin concentrations and urinary
cadmium for both children and adults, but
neither remained significant after adjusting
for creatinine and selected confounders.
Results from previous studies of high occu-
pational cadmium exposures have suggested
that urinary albumin may be a sensitive indi-
cator of cadmium-induced renal effects (7).
Cadmium levels in the high-exposure groups
from these studies ranged from 6 µg to 16
µg cadmium/g creatinine (7), well above the
levels observed in this study’s environmen-
tally exposed population.
We did not observe an association
between β2-microglobulin and urinary cad-
mium. β2-Microglobulin is a low-molecular-
weight protein that is normally reabsorbed
by the renal tubules, and its presence in
urine indicates compromised tubular reab-
sorption function. Currently, α1-microglob-
ulin or retinol-binding protein are more
commonly used as low-molecular-weight
proteins for studies of nephrotoxicity
because of the instability of β2-microglobu-
lin in acidic environments (29,35). Our
analysis of β2-microglobulin was restricted
to urine samples with pH values ≥ 6.0, but
this does not rule out the potential for
breakdown of the protein in the bladder
before excretion. This restriction reduced
the sample size for this biomarker by almost
50% and limited the statistical power to
detect small differences in protein levels
between the highest and lowest exposure
groups.
Conclusions from this study must take
into account some of the recognized limita-
tions. First, because levels of urinary cad-
mium for individuals in the target and
comparison areas were similar, the data from
both groups were combined. Despite similar
demographic characteristics of the two com-
munities, individuals from the more indus-
trialized target community could have a
greater potential for exposure to other
nephrotoxic substances. However, we
observed similar associations between uri-
nary cadmium and kidney biomarkers when
area of residence was included in the multi-
variate models and when the target and
comparison areas were analyzed separately.
Secondly, we used urinary creatinine to
adjust for either highly dilute or highly con-
centrated urine samples, but creatinine levels
can vary by age, sex, and body mass (28).
The multivariate statistical models were
adjusted for age and sex, but data on height
and weight were not available for body mass
adjustment. The use of creatinine to stan-
dardize urinary metal values for children has
been particularly problematic, and exposure
values might be expected to be artificially
inﬂated among this age group (36). The cre-
atinine-adjusted urinary cadmium levels in
this study, however, are significantly lower
among children (Table 1), as would be
expected when this marker of chronic body
burden is used. Finally, we based information
on kidney disease or other health conditions
that may have affected individuals’ kidney
function on self-reported data, and we were
unable to verify these conditions. Under con-
ditions of extensive cadmium-induced renal
tubular damage, urinary cadmium levels
have been shown to rise sharply, but this
effect does not necessarily occur under con-
ditions of tubular dysfunction unrelated to
cadmium exposure (4). The subjects evalu-
ated in this study did not have abnormal lev-
els of the urinary biomarkers that could
indicate extensive renal damage, but we can-
not exclude the possibility of subclinical
renal conditions.
Results of previous investigations have
suggested that proteinuria resulting from
high cadmium exposures has been irreversible
and progressive (13,37), but reversibility of
minor renal changes was found among
workers following a reduction in cadmium
exposure (38). The clinical significance of
the observed relationship between low-level
urinary cadmium and urinary NAG and
AAP is difficult to discern. The association
between increased urinary excretion of NAG
and renal damage has not been fully deter-
mined and may reflect increased lysosomal
activity. Given that cadmium is stored in the
renal tubule, it is possible that the correla-
tion of the metal and these biomarkers is the
result of a common association with another
factor (e.g., the natural turnover rate and
exfoliation of tubular cells). However, in a
study of cancer patients, urinary levels of
NAG and AAP were associated with loss of
renal tubular secretion function in response
to the chemotherapeutic agent cisplatin
(8,9). For low-level cadmium exposure, it is
unclear whether the observed differences in
the levels of these tubular enzymes indicates
subclinical toxicity that may cause cumula-
tive renal deﬁciencies. Results of a 5-year fol-
low-up study in Belgium indicated that a rise
in urinary cadmium over time was a predictor
of an increase in NAG, but there was no
strong evidence that elevated NAG at baseline
resulted in decreases in creatinine clearance or
increases in albumin excretion at follow-up
(39). In another 5-year follow-up study of
populations with low-level cadmium exposure
from three different areas of the United
States, individuals with baseline elevations in
preclinical biomarkers such as NAG and
selected health conditions were more likely to
show early indicators of kidney disease (i.e.,
elevated serum creatinine, elevated serum cys-
tatin C, and decreased creatinine clearance) at
follow-up (40). Further, participants who had
these underlying health conditions at baseline,
yet did not initially have an elevated bio-
marker, appeared to be at lower risk of devel-
oping early clinical signs of kidney disease
than those with these health conditions who
did have elevated kidney biomarkers (40).
Thus, associations between these preclinical
biomarkers and low-level environmental cad-
mium exposures may be particularly relevant
for certain susceptible populations.
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Figure 1. Least-squares mean concentrations (adjusted for age, sex, smoking, and self-reported diabetes
or thyroid disease) of urinary NAG (U/g creatinine) (A) and AAP (U/g creatinine) (B) among adult partici-
pants, summarized by ﬁve categories of creatinine-adjusted urinary cadmium. 
*p < 0.05 compared to the lowest exposure group (< 0.25 µg cadmium/g creatinine). 
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BIn this study, we evaluated renal bio-
markers among a population exposed to lev-
els of cadmium that are similar to those of
the U.S. general population. Whether the
observed changes in excreted enzymes
reﬂects early, irreversible tubular damage or
an overly sensitive indication of subclinical
effects that will never progress to actual renal
dysfunction will require continued follow-up
of low-exposure populations such as these.
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